AI-based liquid biopsy may detect liver fibrosis, cirrhosis and chronic disease signals
Medical Xpress
March 5, 2026
Researchers at the Johns Hopkins Kimmel Cancer Center report that an artificial intelligence (AI)-based liquid biopsy test using genome-wide cell-free DNA (cfDNA) fragmentation patterns and repeat landscapes can detect early liver fibrosis and cirrhosis, and may also reveal signals of broader chronic disease burden. The findings, published in Science Translational Medicine, represent the first time this fragmentome technology, initially studied in cancer, has been applied systematically to detection of chronic noncancer conditions.
Verticals
healthmedical
Originally published on Medical Xpress on 3/5/2026